Frequently Asked Questions

1. **Question:** What is EUFLEXXA?
   **Answer:** Working right at the source of pain, EUFLEXXA is a hyaluronic acid (HA) that’s injected directly into the knee by your healthcare provider. It is sometimes called a “gel shot for the knee.” If you have Osteoarthritis (OA) knee pain, and simple pain medications aren’t giving you the relief you need, talk to your healthcare provider about EUFLEXXA. EUFLEXXA closely resembles healthy HA in the knee. EUFLEXXA is animal-free. It’s created in a controlled environment—with a precise, multi-step cleansing and filtering process. This results in the development of a gel-like fluid.

2. **Question:** After taking EUFLEXXA, how long can my pain relief last?
   **Answer:** Clinical studies show that EUFLEXXA may help provide pain relief for up to 6 months when you get all 3 injections. Each treatment counts when it comes to helping keep your knees relieved from pain and stiffness. Be sure to get all 3 injections to get the full benefit of your treatment. EUFLEXXA offers the HAppy Knees Program to provide helpful appointment reminders, tips, and follow-ups. Just text HAppy to 973-355-7159 from your smartphone to enroll.

3. **Question:** When should I follow-up with my healthcare provider?
   **Answer:** Follow-up with your healthcare provider at 6 months to discuss the result of your treatment, ie relief from OA knee pain, and whether you would benefit from retreatment with EUFLEXXA.

4. **Question:** What types of healthcare providers treat with EUFLEXXA?
   **Answer:** Both primary care physicians and specialists treat OA knee pain with EUFLEXXA. Specialists who give EUFLEXXA may include orthopedic surgeons/orthopedists, rheumatologists, sports medicine physicians, pain management specialists, physiatrists (rehabilitation physicians), and often nurse practitioners and physician assistants.

5. **Question:** How do I know if my insurance covers EUFLEXXA?
   **Answer:** Your healthcare provider’s office will verify your insurance coverage for you. If your plan doesn’t cover EUFLEXXA, your healthcare provider’s office will provide details on how you can buy EUFLEXXA directly.

6. **Question:** I’ve tried lots of simple pain medications and they don’t work. Why should I try EUFLEXXA?
   **Answer:** EUFLEXXA works differently from pain medications such as acetaminophen, ibuprofen, and naproxen. It has helped people who couldn’t find relief from these everyday pain medications. EUFLEXXA has also been used when exercise and physical therapy don’t offer enough relief.

7. **Question:** What are the side effects of EUFLEXXA?
   **Answer:** The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

**IMPORTANT SAFETY INFORMATION**
- Do not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products.
- You should not have EUFLEXXA injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.

Please see complete Important Safety Information and Indication on page 2 and Full Prescribing Information on pages 3 and 4.
8. Question: Will the injections hurt?
Answer: While injection pain is very individual, numbing agents are typically applied to the knee before EUFLEXXA is given to offset any potential discomfort. Regardless of whether or not you experience discomfort after the first injection, you should still get all 3 injections for maximum pain relief.\(^2\),\(^4\)

9. Question: Can both my knees be treated with EUFLEXXA at the same time?
Answer: Yes. Ask your healthcare provider what will work best for you. If you have pain in both knees, also known as bilateral OA, get 3 injections in each knee to get the full benefit of EUFLEXXA.\(^2\),\(^4\)

10. Question: How satisfied are patients who have taken EUFLEXXA?
Answer: In a 12-week study, in which EUFLEXXA was shown to be comparable to another HA at reducing pain associated with 5 activities, overall patient satisfaction was high. Over 8 out of 10 patients treated with EUFLEXXA were satisfied with their reduction in OA knee pain.\(^14\)

11. Question: How do I get EUFLEXXA?
Answer: Most healthcare providers stock EUFLEXXA, and most insurance providers cover EUFLEXXA. If yours doesn't, please visit http://euflexxa.com/how-do-i-get-euflexxa/ or refer to the EUFLEXXA patient brochure provided by your healthcare provider.

**IMPORTANT SAFETY INFORMATION (cont.)**

- EUFLEXXA has not been tested in pregnant women, women who are nursing or in children less than 18 years of age. After you receive your EUFLEXXA injection you should avoid physical activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time).
- The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.
You may also contact Ferring Pharmaceuticals Inc. at 1-888-FERRING.


**INDICATION**

EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.

Please see Full Prescribing Information on next page.

EUFLEXXA\(^\text{TM}\) is a registered trademark of Ferring B.V © 2018 Ferring B.V.
The most common adverse events related to EUFLEXXA injections reported in the clinical studies are the following:

- Transient pain and/or swelling of the injected joint may occur after intra-articular injection of EUFLEXXA.
- Do not use after expiration date.
- Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.
- Remove any joint effusion before injecting.
- Patients having repeated exposure to EUFLEXXA have the potential for an immune response; however, this reaction is generally benign.
- Do not inject intravascularly because intravascular injection may cause systemic adverse events.
- Mixing of quaternary ammonium salts such as benzalkonium chloride with hyaluronan solutions results in gel destabilization.
- Do not use EUFLEXXA to treat patients who have a known hypersensitivity to hyaluronan preparations.
- Analgesics (e.g., acetaminophen) should be used to treat pain that may occur after EUFLEXXA injection.

ADVERSE REACTIONS

Pain in joint: Transient or prolonged pain may occur in the joint following injection of product. Pain may be mild, moderate, or severe and may last minutes to months. Injection may be painful, and injection technique may affect pain.

Injection site: Transient injection site tenderness (e.g., bruising, blue or red discoloration, hard or soft swelling, inflammation) may occur following injection of product, especially at a site with inflammation. Injection site tenderness may last minutes to weeks. Injection of product into inflamed tissue may be painful.

Systemic: Transient fever may occur following injection of product. Transient fever may be mild or severe and may last minutes to months. Injection may be painful, and injection technique may affect pain.

Skin and subcutaneous tissue: Transient local skin reactions may occur, such as irritation, redness, discoloration, tenderness, or pruritus. These reactions may last minutes to weeks.

Nervous system: Transient headache may occur following injection of product. Transient headache may be mild, moderate, or severe and may last minutes to months. Injection may be painful, and injection technique may affect pain.

Musculoskeletal and connective tissue: Transient joint pain may occur following injection of product. Joint pain may be mild, moderate, or severe and may last minutes to months. Injection may be painful, and injection technique may affect pain.

Eye: Transient local ocular reactions may occur, such as irritation, redness, discoloration, tenderness, or pruritus.

Infections and infestations: Transient local infections may occur, such as irritation, redness, discoloration, tenderness, or pruritus.

Irritating: Transient local irritation reactions may occur, such as irritation, redness, discoloration, tenderness, or pruritus.

Ocular: Transient local ocular irritation may occur following injection of product. Transient ocular irritation may be mild, moderate, or severe and may last minutes to months.
WHAT SHOULD I DO AFTER RECEIVING A EUFLEXXA INJECTION?

- Avoid physical activity for 4 hours following the injection to keep the joint from swelling.
- Rest.
- Keep the knees warm.
- Avoid bending your knees greater than 90 degrees for 48 hours.
- Ice and Tylenol® as needed for pain.
- Do not bend your knee for more than one hour at a time during the first 24 hours following your injection of EUFLEXXA.
- You should ask your doctor if you should begin physical activity again.

WHAT SHOULD I CALL MY DOCTOR (TROUBLESHOOTING)?
- If you have persistent pain or swelling, contact your doctor immediately.

WHAT OTHER NON-SURGICAL TREATMENTS ARE AVAILABLE FOR OSTEARTHROIS?
- Non-drug treatments
  - Avoiding activities that cause pain in your knee
  - Exercise therapy
  - Physical therapy

- Drugs that reduce inflammation, such as aspirin and other non-steroidal anti-inflammatory agents (NSAIDs) such as ibuprofen and naproxen.

WHAT ARE THE CLINICAL STUDIES WITH EUFLEXXA DEPOT?
A clinical trial involving 201 patients with knee pain due to osteoarthritis was performed in Germany. The study compared EUFLEXXA against a placebo (saline). In total, 201 patients were enrolled in the study and treated for 26 weeks.

- Pain, stiffness and function of the knee joint and patients’ and doctors’ assessments were measured.

- The pain scores were used to compare the effectiveness of EUFLEXXA over time.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.

- The study found a significant improvement in osteoarthritis knee pain relief with the use of EUFLEXXA.

- The saline group improved 18.5 mm. There was more improvement with EUFLEXXA.

- EUFLEXXA showed a larger mean decrease in pain scores on the 50-foot walk test, measured on a 100mm horizontal VAS score at 26 weeks.

- The analysis is based on repeated measure mixed model Analysis of Covariance (ANCOVA) from baseline through 26 weeks on mean change from baseline 50-foot walk test, measured on a 100mm horizontal VAS score.